MIrabegron With oveRACtive bLadder Symptoms in mEn
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The proportion of male patients who participated in the phase III study of mirabegron was
about 28% and the data on the efficacy and safety of mirabegron in Korean male OAB patients
have limits. For this reason, this study will assess the efficacy and safety of mirabegron in
Korean male OAB patients.